Cargando…

Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study

INTRODUCTION: The objective of the study was to describe the pharmacokinetics (PK) of fluconazole, anidulafungin, and caspofungin in critically ill patients and to compare with previously published data. We also sought to determine whether contemporary fluconazole doses achieved PK/pharmacodynamic (...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinnollareddy, Mahipal G, Roberts, Jason A, Lipman, Jeffrey, Akova, Murat, Bassetti, Matteo, De Waele, Jan J, Kaukonen, Kirsi-Maija, Koulenti, Despoina, Martin, Claude, Montravers, Philippe, Rello, Jordi, Rhodes, Andrew, Starr, Therese, Wallis, Steven C, Dimopoulos, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335513/
https://www.ncbi.nlm.nih.gov/pubmed/25888060
http://dx.doi.org/10.1186/s13054-015-0758-3
_version_ 1782358357636546560
author Sinnollareddy, Mahipal G
Roberts, Jason A
Lipman, Jeffrey
Akova, Murat
Bassetti, Matteo
De Waele, Jan J
Kaukonen, Kirsi-Maija
Koulenti, Despoina
Martin, Claude
Montravers, Philippe
Rello, Jordi
Rhodes, Andrew
Starr, Therese
Wallis, Steven C
Dimopoulos, George
author_facet Sinnollareddy, Mahipal G
Roberts, Jason A
Lipman, Jeffrey
Akova, Murat
Bassetti, Matteo
De Waele, Jan J
Kaukonen, Kirsi-Maija
Koulenti, Despoina
Martin, Claude
Montravers, Philippe
Rello, Jordi
Rhodes, Andrew
Starr, Therese
Wallis, Steven C
Dimopoulos, George
author_sort Sinnollareddy, Mahipal G
collection PubMed
description INTRODUCTION: The objective of the study was to describe the pharmacokinetics (PK) of fluconazole, anidulafungin, and caspofungin in critically ill patients and to compare with previously published data. We also sought to determine whether contemporary fluconazole doses achieved PK/pharmacodynamic (PD; PK/PD) targets in this cohort of intensive care unit patients. METHODS: The Defining Antibiotic Levels in Intensive care unit patients (DALI) study was a prospective, multicenter point-prevalence PK study. Sixty-eight intensive care units across Europe participated. Inclusion criteria were met by critically ill patients administered fluconazole (n = 15), anidulafungin (n = 9), and caspofungin (n = 7). Three blood samples (peak, mid-dose, and trough) were collected for PK/PD analysis. PK analysis was performed by using a noncompartmental approach. RESULTS: The mean age, weight, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores of the included patients were 58 years, 84 kg, and 22, respectively. Fluconazole, caspofungin, and anidulafungin showed large interindividual variability in this study. In patients receiving fluconazole, 33% did not attain the PK/PD target, ratio of free drug area under the concentration-time curve from 0 to 24 hours to minimum inhibitory concentration (fAUC(0–24)/MIC) ≥100. The fluconazole dose, described in milligrams per kilogram, was found to be significantly associated with achievement of fAUC(0–24)/MIC ≥100 (P = 0.0003). CONCLUSIONS: Considerable interindividual variability was observed for fluconazole, anidulafungin, and caspofungin. A large proportion of the patients (33%) receiving fluconazole did not attain the PK/PD target, which might be related to inadequate dosing. For anidulafungin and caspofungin, dose optimization also appears necessary to minimize variability. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-015-0758-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4335513
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43355132015-02-21 Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study Sinnollareddy, Mahipal G Roberts, Jason A Lipman, Jeffrey Akova, Murat Bassetti, Matteo De Waele, Jan J Kaukonen, Kirsi-Maija Koulenti, Despoina Martin, Claude Montravers, Philippe Rello, Jordi Rhodes, Andrew Starr, Therese Wallis, Steven C Dimopoulos, George Crit Care Research INTRODUCTION: The objective of the study was to describe the pharmacokinetics (PK) of fluconazole, anidulafungin, and caspofungin in critically ill patients and to compare with previously published data. We also sought to determine whether contemporary fluconazole doses achieved PK/pharmacodynamic (PD; PK/PD) targets in this cohort of intensive care unit patients. METHODS: The Defining Antibiotic Levels in Intensive care unit patients (DALI) study was a prospective, multicenter point-prevalence PK study. Sixty-eight intensive care units across Europe participated. Inclusion criteria were met by critically ill patients administered fluconazole (n = 15), anidulafungin (n = 9), and caspofungin (n = 7). Three blood samples (peak, mid-dose, and trough) were collected for PK/PD analysis. PK analysis was performed by using a noncompartmental approach. RESULTS: The mean age, weight, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores of the included patients were 58 years, 84 kg, and 22, respectively. Fluconazole, caspofungin, and anidulafungin showed large interindividual variability in this study. In patients receiving fluconazole, 33% did not attain the PK/PD target, ratio of free drug area under the concentration-time curve from 0 to 24 hours to minimum inhibitory concentration (fAUC(0–24)/MIC) ≥100. The fluconazole dose, described in milligrams per kilogram, was found to be significantly associated with achievement of fAUC(0–24)/MIC ≥100 (P = 0.0003). CONCLUSIONS: Considerable interindividual variability was observed for fluconazole, anidulafungin, and caspofungin. A large proportion of the patients (33%) receiving fluconazole did not attain the PK/PD target, which might be related to inadequate dosing. For anidulafungin and caspofungin, dose optimization also appears necessary to minimize variability. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-015-0758-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-04 2015 /pmc/articles/PMC4335513/ /pubmed/25888060 http://dx.doi.org/10.1186/s13054-015-0758-3 Text en © Sinnollareddy et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Sinnollareddy, Mahipal G
Roberts, Jason A
Lipman, Jeffrey
Akova, Murat
Bassetti, Matteo
De Waele, Jan J
Kaukonen, Kirsi-Maija
Koulenti, Despoina
Martin, Claude
Montravers, Philippe
Rello, Jordi
Rhodes, Andrew
Starr, Therese
Wallis, Steven C
Dimopoulos, George
Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
title Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
title_full Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
title_fullStr Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
title_full_unstemmed Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
title_short Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
title_sort pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (dali) patients study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335513/
https://www.ncbi.nlm.nih.gov/pubmed/25888060
http://dx.doi.org/10.1186/s13054-015-0758-3
work_keys_str_mv AT sinnollareddymahipalg pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT robertsjasona pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT lipmanjeffrey pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT akovamurat pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT bassettimatteo pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT dewaelejanj pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT kaukonenkirsimaija pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT koulentidespoina pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT martinclaude pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT montraversphilippe pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT rellojordi pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT rhodesandrew pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT starrtherese pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT wallisstevenc pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT dimopoulosgeorge pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy
AT pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy